CLOSE
  • Research activities

    Group Members

    Gaia Sambruni (PhD student)

     

    We are interested how alterations of the DNA transform a healthy into a malignant cell. 10,000s of human genomes and epigenomes have been sequenced over the last years. These efforts uncovered a large number of genetic or epigenetic alterations in cancer patients. Given this large number of alterations it is difficult to tell which of those contribute to disease progression.

    Cancer development is a process that often takes many years. During this time cancer cells vary, compete and the fittest survive. We are studying the evolutionary principles underlying this process and try to understand how the environment modulates cancer evolution and contributes to the molecular variation between cancers from different tissues.

    Another focus of our lab is to understand how genes work together to create complex phenotypes such as cancer. Traditionally, genes have been studied in isolation. We develop methods using tools from network and systems biology to better understand the interplay between different alterations in cancer genomes and epigenomes.

    Ultimately, our goal is to understand the impact of genomic and epigenomic varition on patient phenotypes such as survival or drug response. We thereby support the development of diagnostic and personalized therapeutic approaches.

  • Relevant publications

    • Dmitrijeva M, Ossowski S, Serrano L and Schaefer MH. Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates. 2018. Nucleic Acids Research. 46(14):7022-7039.
    • Zapata L, Pich O, Serrano L, Kondrashov F, Ossowski S and Schaefer MH. Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. 2018. Genome biology. 19(1):67.
    • Cramer D, Serrano L and Schaefer MH. A network of epigenetic modifiers and DNA repair genes controls tissue-specific copy number alteration preference.2016. eLife. 5. pii: e16519.

PARTNERSHIP

Università degli Studi di Milano Ecancer Medical Science IFOM-IEO Campus

CREDITS

Ministero della Salute Joint Commission International Breastcertification bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153 - Codice intermediario fatturazione elettronica: A4707H7

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO